Sensex
74,616.58 profit arw 509.73 (0.69%)
Nifty
23,123.65 profit arw 155.40 (0.68%)
Nasdaq
18,355.20 profit arw -497.09 (-2.64%)
logo img

GET IN TOUCH

GET IN TOUCH

Refresh Captcha
Equity

As on : 07-Apr-2026
Corporate News
07-Apr-2026     20:10

Aurobindo Pharma receives USFDA approval for Dapagliflozin and Metformin Hydrochloride XR Tablets

Aurobindo Pharma announced that the final approval is received from the US Food & Drug Administration (USFDA) to manufacture and market Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets, 5 mg/ 500 mg, 5 mg/1000 mg, 10 mg/500 mg, and 10 mg/1000 mg, which is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Xigduo XR Tablets, 5 mg/ 500 mg, 5 mg/1000 mg, 10 mg/500 mg, and 10 mg/1000 mg, of AstraZeneca AB. These products will be manufactured at Unit-IV of APL Healthcare, a wholly owned subsidiary of the Company and will be launched immediately.

INDIAN INDICES

Sensex

74,616.58 509.73 (0.69%)

Nifty

23,123.65 155.40 (0.68%)

GLOBAL INDICES

USD

NA

NASDAQ
HANG SENG

25,116.54 -177.50(-0.70%)